论文部分内容阅读
胰腺内分泌瘤较常见的有胰岛素瘤、胃泌素瘤和腹高糖素瘤,而生长抑素瘤和分泌VIP、ACTH、促肾上腺皮质释放因子或胰多肽的肿瘤则极为罕见。大多数胰腺内分泌瘤生长缓慢,决定能否长期生存的主要因素是病变的范围。然而,有5～10%胰岛素瘤,23～90%胃泌素瘤和70～75%胰高糖素瘤发生转移,诊断为胰岛细胞癌的病人,其5年生存率仅为30～35%,由于这类病人在全美国每年不超过600例,缺乏系统研究,至今对转移性胰腺内分泌瘤的最佳治疗方案尚待探索。
Pancreatic endocrine tumors are more common with insulinomas, gastrinomas, and abdominal hyperglycoma tumors, while somatostatin tumors and tumors that secrete VIP, ACTH, adrenocortical release factor, or pancreatic polypeptide are extremely rare. Most pancreatic endocrine tumors grow slowly, and the main factor that determines the long-term survival is the extent of the disease. However, 5 to 10% of insulinomas, 23 to 90% of gastrinomas, and 70 to 75% of glucagonomas metastasize. Patients diagnosed with islet cell carcinoma have a 5-year survival rate of only 30 to 35%. Since these patients do not have more than 600 cases per year in the United States and lack systematic research, the best treatment for metastatic pancreatic endocrine tumors remains to be explored.